Clinical Trial Update: A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating different modified-release formulations of GSK2982772 compared to immediate-release, including repeat-dose PK, complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Diseases

Drugs mentioned

• GSK2982772 (GSK2982772)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Autoimmune Diseases | Phase 1 | Status: COMPLETED | Results posted: 2020-01-09